Stem Cell Therapy for Knee Osteoarthritis: What Patients Should Know
Knee osteoarthritis is the single most common reason people buy stem cell treatment. It is also the condition with the most useful evidence — which makes it the best place to understand what these treatments really do.
The honest summary: patients genuinely improve after these injections. Most of that improvement does not appear to come from the cells.
What the treatment involves
Mesenchymal stromal cells — from your own bone marrow or fat, or from donated umbilical cord tissue — are injected into the knee joint, usually under ultrasound guidance, as a single outpatient procedure. Cost is typically $5,000–$12,000 per knee in the US and $3,000–$8,000 in Mexico.
The stated aim varies by clinic. Some claim cartilage regeneration. Some describe reducing inflammation. The second is more plausible than the first.
What randomised trials found
A 2025 systematic review and meta-analysis pooled eight randomised controlled trials covering 467 patients, comparing intra-articular MSC injection against an inert placebo injection. Its findings are the most important thing on this page.
| Time point | Pain improvement from contextual effects | Function improvement from contextual effects |
|---|---|---|
| 6 months | ~63% | ~61% |
| 12 months | ~50% | ~66% |
The authors concluded that "the majority of symptomatic improvement following intra-articular MSC injections is attributable to contextual (placebo) effects, whereas the MSCs themselves confer only a modest incremental benefit." The certainty of the evidence was rated low, owing to small trial sizes, methodological concerns and possible reporting bias.
What that actually means
It does not mean patients are imagining anything. The improvement measured in these trials is real, substantial, and shows up on validated pain and function scores. People genuinely hurt less.
What it means is that most of that relief also occurred in the patients who received a placebo injection. Expectation, the ritual of an expensive medical procedure, attentive clinical care, and natural fluctuation in arthritis symptoms together account for the larger share.
The researchers described this as resolving an "efficacy paradox" — why clinics honestly report high satisfaction while controlled trials find only small differences between groups. Both observations are true at once.
What this changes about the decision
If roughly half to two-thirds of the benefit would occur with a placebo, the practical question becomes: what is the fair price for the remainder? A $10,000 injection where the incremental effect over placebo is modest is a different purchase than the one most clinic websites describe.
Does it regrow cartilage?
There is no reliable evidence that these injections regenerate cartilage in human knees. Imaging studies have not demonstrated meaningful cartilage restoration. Where benefit occurs, the most plausible mechanism is anti-inflammatory signalling rather than tissue regeneration.
Be sceptical of before-and-after MRI images presented without independent radiological assessment.
Is it FDA approved?
No. No stem cell product is FDA approved for knee osteoarthritis. See the full FDA breakdown.
How it compares to the alternatives
| Option | Evidence | Typical cost | Covered by insurance |
|---|---|---|---|
| Exercise therapy and weight management | Strong; recommended first-line in every major guideline | Low | Usually |
| Corticosteroid injection | Good short-term pain relief | $100–$300 | Usually |
| Hyaluronic acid injection | Mixed; guidelines conflict | $300–$1,500 | Sometimes |
| Platelet-rich plasma | Moderate, better than commonly assumed | $500–$2,000 | No |
| Stem cell injection | Low certainty; mostly placebo-attributable | $5,000–$12,000 | No |
| Total knee replacement | Strong, decades of outcome data | $30,000–$50,000 | Usually |
Notably, PRP has evidence at least comparable to stem cell injection at a fraction of the price. PRP vs stem cells.
Who might reasonably still consider it
Someone with moderate osteoarthritis who has exhausted conservative options, is not yet a candidate for or does not want joint replacement, understands the treatment is unproven, and can afford the cost without borrowing — may reasonably decide the modest incremental benefit is worth trying.
That is a defensible decision made with accurate information. What is not defensible is making it because a clinic implied the cells would regrow the joint.
Questions for your clinic
- What cell type, source, dose and viability?
- Which randomised controlled trial supports this for knee osteoarthritis?
- How do you respond to the finding that most measured benefit is contextual?
- What outcome measure do you use, and what are your twelve-month results?
- Is the price per knee or per session?
Sources
- Contextual effects of mesenchymal stem cell injections for knee osteoarthritis: systematic review and meta-analysis of randomised controlled trials. Frontiers in Medicine, 2025.
- Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: systematic review and meta-analysis of RCTs. PubMed, 2025.
- US Food and Drug Administration — Approved Cellular and Gene Therapy Products.
Not sure whether this is right for you?
Tell us about your condition and we will send you our free clinic-vetting checklist, an honest summary of the evidence for your situation, and — where they exist — free clinical trials you may be eligible for. Get matched with a vetted clinic
Medical disclaimer
This article is for general information and is not medical advice. We are not a healthcare provider and do not diagnose or treat any condition. Most stem cell treatments discussed here are not FDA approved for these uses, outcomes vary, and no result is guaranteed. Always speak with a licensed physician who knows your history. See our medical disclaimer and how we make money.